Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Gastrointestinal Stromal Tumors 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × pexidartinib × Clear all
NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

University of California, San Francisco

Phase 1/2 Completed
67 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡